Previous research has demonstrated that the expression of the calcium-activated potassium channel (Kca 3.1) is higher in patients with idiopathic pulmonary fibrosis (IPF), and that genetic and pharmacological inhibition of Kca3.1 was able to prevent or attenuate fibrosis.